Status:
COMPLETED
Transnasal Versus Suprazygomatic SPG Block in Persistant Idiopathic Facial Pain
Lead Sponsor:
Diskapi Teaching and Research Hospital
Conditions:
Headache
Persistent Idiopathic Facial Pain
Eligibility:
All Genders
18+ years
Brief Summary
The International Headache Society defines persistent idiopathic facial pain (PIFP) as persistent facial pain that does not have the characteristics of cranial neuralgia, is blunt, persistent, persist...
Detailed Description
Patients with chronic head and facial pain are frequently referred to us and some of these patients are persistent idiopathic facial pain patients who do not respond to conservative treatment. Various...
Eligibility Criteria
Inclusion
- Diagnosis of persistent idiopathic facial pain according to ICHD-3 beta criteria
- Moderate to severe pain (pain of 6 or more on a numeric pain scale of 0-10)
- Persistence of pain for more than 6 months
- Pain unresponsive to conservative methods
Exclusion
- Presence of secondary headache (tumor, bleeding, stroke, etc.)
- Cognitive impairment
- Hepatic or renal insufficiency
- Local or systemic infection
- Coagulopathy
- Patient refusal to accept treatment
Key Trial Info
Start Date :
October 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 2 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06496841
Start Date
October 1 2022
End Date
April 2 2023
Last Update
August 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ankara Etlik City Hospital
Ankara, Yenimahalle, Turkey (Türkiye), 06100